Contineum Therapeutics Inc Class A Common Stock CTNM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
-
Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
-
Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis
Trading Information
- Previous Close Price
- $18.84
- Day Range
- $18.63–19.20
- 52-Week Range
- $13.27–22.00
- Bid/Ask
- $18.87 / $19.29
- Market Cap
- $493.89 Mil
- Volume/Avg
- 4,382 / 72,221
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.contineum-tx.com
Comparables
Valuation
|
Metric
|
CTNM
|
FULC
|
UTHR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 18.27 |
Price/Book Value | 2.23 | 0.86 | 2.80 |
Price/Sales | — | 2.90 | 6.74 |
Price/Cash Flow | — | — | 14.46 |
Price/Earnings
CTNM
FULC
UTHR
Financial Strength
|
Metric
|
CTNM
|
FULC
|
UTHR
|
|---|---|---|---|
Quick Ratio | 58.48 | 21.84 | 3.92 |
Current Ratio | 58.92 | 22.07 | 4.35 |
Interest Coverage | — | — | 22.67 |
Quick Ratio
CTNM
FULC
UTHR
Profitability
|
Metric
|
CTNM
|
FULC
|
UTHR
|
|---|---|---|---|
Return on Assets (Normalized) | −18.15% | −1.76% | 16.95% |
Return on Equity (Normalized) | −871.68% | −1.91% | 20.53% |
Return on Invested Capital (Normalized) | −892.99% | −1.83% | 16.62% |
Return on Assets
CTNM
FULC
UTHR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Rqcktzjwk | Pgpq | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tqfxlhph | Yfyghnb | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rcrtgcsl | Kxzmz | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Prwdypfj | Xvzkzkq | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Tvjkzlrhj | Rsc | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Xlmqfqsbq | Lbd | $28.1 Bil | |||
| Moderna Inc
MRNA
| Crdwcnks | Vdhh | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Ynhlhqmd | Tbjl | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Cvvnmqrmd | Rxsntg | $13.4 Bil | |||
| Incyte Corp
INCY
| Htcwdfbgr | Vngvtjl | $12.7 Bil |
United States